Observational Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Endosc. Mar 16, 2022; 14(3): 153-162
Published online Mar 16, 2022. doi: 10.4253/wjge.v14.i3.153
SARS-CoV-2 in inflammatory bowel disease population: Antibodies, disease and correlation with therapy
Clara Benedetta Conti, Elsa Mainardi, Sara Soro, Sophie Testa, Annalisa De Silvestri, Andrea Drago, Fabrizio Cereatti, Roberto Grassia
Clara Benedetta Conti, Sara Soro, Andrea Drago, Fabrizio Cereatti, Roberto Grassia, Department of Gastroenterology and Digestive Endoscopy, ASST Cremona, Cremona 26100, Italy
Elsa Mainardi, Sophie Testa, Department of Laboratory Medicine, Haemostasis and Thrombosis Center, ASST Cremona, Cremona 26100, Italy
Annalisa De Silvestri, Department of Clinic Epidemiology and Biometric, Scientific Direction, Fondazione IRCCS Policlinico San Matteo, Pavia 27100, Italy
Author contributions: Conti CB and Grassia R conceived and planned the study; Mainardi E, Grassia R, Drago A, Cereatti F, Soro S and Testa S carried out the tests and collected the data; Testa S and Mainardi E contributed to the interpretation of the results; De Silvestri A performed the statistical analysis; Conti CB wrote the manuscript; all authors provided critical feedback and helped the research and analysis of the manuscript.
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board Comitato EticoVal Padana.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: No conflict of interest.
Data sharing statement: Technical appendix, statistical code, and data set available from the corresponding author at benedetta.conti1@gmail.com. Participants gave informed consent for data collection and data are recorded anonymized. Risk of identification is very low.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Clara Benedetta Conti, MD, Consultant Physician-Scientist, Department of Gastroenterology and Digestive Endoscopy, ASST Cremona, Viale Concordia 1, Cremona 26100, Italy. benedetta.conti1@gmail.com
Received: October 11, 2021
Peer-review started: October 11, 2021
First decision: December 3, 2021
Revised: December 14, 2021
Accepted: February 16, 2022
Article in press: February 16, 2022
Published online: March 16, 2022
Processing time: 155 Days and 22.6 Hours
Core Tip

Core Tip: Guidelines recommend ceasing inflammatory bowel disease (IBD) biologic therapy during coronavirus disease 2019 (COVID-19). IBD patients were prospectively tested for severe acute respiratory syndrome coronavirus 2 IgG. In total, 103 IBD patients were enrolled. We found that 18.4% had IgG positivity, and 63% developed COVID-19 disease with symptoms. However, all but one patient with symptoms did not require ceasing IBD treatment no hospitalization. None of the patients under biologic therapy developed severe COVID-19. Therefore, the IBD population does not seem to have a high risk of severe COVID-19, particularly if under biological treatment or mesalazine.